Use of heparin to prevent lung microvascular thrombosis in patients administered aprotinin undergoing cardiac surgery for ischemic heart disease

Use of heparin to prevent lung microvascular thrombosis in patients administered aprotinin undergoing cardiac surgery for ischemic heart disease for ischemic heart disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000328572

Enrollment

Registered

2006-08-03

Start date

2006-08-08

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Patients undergoing cardiac surgery administered aprotinin will be enrolled. Patients will be randomised to receive a pre-operative heaprin infusion or placebo. A lung biopsy will be taken to determine if pre-operative heaprin prevents the development of microvascular thrombosis in the lungs. Hypothesis. Heparin prevents the formation of blood clots in the lungs following cardiac surgery. The patients enrolled, the therapists and the data collectors will all be blinded.

Interventions

Therapeutic heparin intravenous infusion (18U/kg/Hr) over the 3 hours prior to commencement of surgery.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Elective cardiac surgery.

Exclusion criteria

Repeat cardiac surgery , complex surgery.

Outcome results